PRESS RELEASE published on 03/20/2025 at 07:00, 24 days 11 hours ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2024. Détails de l'événement et informations pratiques disponibles sur www.innate-pharma.com Résultats Financiers Webcast Conférence Téléphonique Innate Pharma Biotechnologies
PRESS RELEASE published on 03/20/2025 at 07:00, 24 days 11 hours ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 month 24 days ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 month 24 days ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 month 24 days ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
PRESS RELEASE published on 02/17/2025 at 07:02, 1 month 24 days ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 01/27/2025 at 07:05, 2 months 17 days ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 2 months 17 days ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
PRESS RELEASE published on 01/27/2025 at 07:00, 2 months 17 days ago Informations privilégiées / Autres communiqués Innate Pharma annonce le traitement du premier patient dans l'essai de phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées Innate Pharma Tumeurs Solides Conjugué Anticorps-médicament IPH4502 Nectine-4
PRESS RELEASE published on 01/27/2025 at 07:00, 2 months 17 days ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
Published on 04/12/2025 at 15:45, 1 day 2 hours ago New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 1 day 16 hours ago Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 1 day 18 hours ago Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/11/2025 at 23:45, 1 day 18 hours ago Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties
Published on 04/11/2025 at 21:45, 1 day 20 hours ago OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:23, 2 days ago EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:30, 2 days ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:30, 2 days ago Reclassement d'actions au sein du concert familial Feuillet sans incidence sur le contrôle de la société
Published on 04/11/2025 at 18:00, 2 days ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2025
Published on 04/11/2025 at 18:00, 2 days ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
